Rhumbline Advisers Catalent, Inc. Transaction History

Rhumbline Advisers

$109 Billion
Q3 2024

A detailed history of Rhumbline Advisers transactions in Catalent, Inc. stock. As of the latest transaction made, Rhumbline Advisers holds 323,916 shares of CTLT stock, worth $19.8 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares

323,916

Previous 328,524 1.4%

Holding current value

$19.8 Million

Previous $18.5 Million 6.21%

% of portfolio

0.02%

Previous 0.02%

29 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 12, 2024	SELL	$56.16 - $60.96 $258,785 - $280,903	-4,608 Reduced 1.4%	323,916 $19.6 Million
Q2 2024 Aug 01, 2024	BUY	$53.58 - $57.02 $96,336 - $102,521	1,798 Added 0.55%	328,524 $18.5 Million
Q1 2024 May 09, 2024	BUY	$42.56 - $59.82 $170,920 - $240,237	4,016 Added 1.24%	326,726 $18.4 Million
Q4 2023 Feb 08, 2024	BUY	$32.18 - $46.57 $140,884 - $203,883	4,378 Added 1.38%	322,710 $14.5 Million
Q3 2023 Nov 09, 2023	BUY	$44.2 - $50.2 $11,624 - $13,202	263 Added 0.08%	318,332 $14.5 Million
Q2 2023 Aug 08, 2023	SELL	$31.86 - $67.26 $345,234 - $728,829	-10,836 Reduced 3.29%	318,069 $13.8 Million
Q1 2023 May 11, 2023	BUY	$45.44 - $74.26 $359,748 - $587,916	7,917 Added 2.47%	328,905 $21.6 Million
Q4 2022 Feb 14, 2023	BUY	$41.39 - $81.0 $734,713 - $1.44 Million	17,751 Added 5.85%	320,988 $14.4 Million
Q3 2022 Nov 10, 2022	BUY	$72.36 - $113.1 $462,525 - $722,935	6,392 Added 2.15%	303,237 $21.9 Million
Q2 2022 Aug 11, 2022	BUY	$87.2 - $114.05 $3.31 Million - $4.33 Million	38,001 Added 14.68%	296,845 $31.8 Million
Q1 2022 May 12, 2022	SELL	$94.19 - $124.49 $1.02 Million - $1.35 Million	-10,880 Reduced 4.03%	258,844 $28.7 Million
Q4 2021 Feb 10, 2022	BUY	$119.57 - $139.07 $1.34 Million - $1.56 Million	11,225 Added 4.34%	269,724 $34.5 Million
Q3 2021 Nov 12, 2021	SELL	$109.17 - $142.35 $429,365 - $559,862	-3,933 Reduced 1.5%	258,499 $34.4 Million
Q2 2021 Aug 05, 2021	SELL	$100.34 - $115.69 $476,715 - $549,643	-4,751 Reduced 1.78%	262,432 $28.4 Million
Q1 2021 May 06, 2021	SELL	$101.51 - $125.27 $292,856 - $361,403	-2,885 Reduced 1.07%	267,183 $28.1 Million
Q4 2020 Feb 10, 2021	BUY	$85.88 - $105.36 $765,190 - $938,757	8,910 Added 3.41%	270,068 $28.1 Million
Q3 2020 Nov 12, 2020	SELL	$72.74 - $92.5 $13.4 Million - $17 Million	-183,811 Reduced 41.31%	261,158 $22.4 Million
Q2 2020 Aug 13, 2020	BUY	$48.02 - $79.04 $971,780 - $1.6 Million	20,237 Added 4.76%	444,969 $32.6 Million
Q1 2020 May 06, 2020	BUY	$36.95 - $62.95 $2.02 Million - $3.44 Million	54,641 Added 14.76%	424,732 $22.1 Million
Q4 2019 Feb 05, 2020	BUY	$47.06 - $56.64 $284,430 - $342,332	6,044 Added 1.66%	370,091 $20.8 Million
Q3 2019 Oct 23, 2019	SELL	$47.45 - $58.05 $182,397 - $223,144	-3,844 Reduced 1.04%	364,047 $17.4 Million
Q2 2019 Aug 14, 2019	SELL	$39.26 - $54.21 $240,231 - $331,710	-6,119 Reduced 1.64%	367,891 $19.9 Million
Q1 2019 May 01, 2019	SELL	$29.84 - $43.92 $172,027 - $253,198	-5,765 Reduced 1.52%	374,010 $15.2 Million
Q4 2018 Jan 31, 2019	BUY	$29.95 - $46.34 $3.16 Million - $4.89 Million	105,456 Added 38.44%	379,775 $11.8 Million
Q3 2018 Nov 07, 2018	BUY	$40.12 - $45.55 $554,057 - $629,045	13,810 Added 5.3%	274,319 $12.5 Million
Q2 2018 Aug 06, 2018	SELL	$38.72 - $42.52 $49,213 - $54,042	-1,271 Reduced 0.49%	260,509 $10.9 Million
Q1 2018 May 02, 2018	SELL	$39.4 - $47.39 $581,268 - $699,144	-14,753 Reduced 5.33%	261,780 $10.7 Million
Q4 2017 Feb 09, 2018	BUY	$37.27 - $43.02 $1.02 Million - $1.18 Million	27,430 Added 11.01%	276,533 $11.4 Million
Q3 2017 Nov 06, 2017	BUY	$33.75 - $41.67 $8.41 Million - $10.4 Million	249,103	249,103 $9.94 Million

Others Institutions Holding CTLT

# of Institutions

513

Shares Held

149M

Call Options Held

575K

Put Options Held

2.03M

View Full List

About Catalent, Inc.

Ticker CTLT
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 179,896,000
Market Cap $11B
Description
Catalent, Inc., together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. The Softgel and Oral Technologies segment provides formulation, development, and manufacturing services for soft capsules for use in a range of customer products,...

More about CTLT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Rhumbline Advisers, based on Form 13F filings with the SEC.

News

Stay updated on Rhumbline Advisers with notifications on news.

Account

Rhumbline Advisers Catalent, Inc. Transaction History